Literature DB >> 20647769

Generation of antisera to purified prions in lipid rafts.

Robert Hnasko1, Ana V Serban, George Carlson, Stanley B Prusiner, Larry H Stanker.   

Abstract

Prion diseases are fatal neurodegenerative disorders caused by prion proteins (PrP). Infectious prions accumulate in the brain through a template-mediated conformational conversion of endogenous PrP(C) into alternately folded PrP(Sc). Immunoassays toward pre-clinical detection of infectious PrP(Sc) have been confounded by low-level prion accumulation in non-neuronal tissue and the lack of PrP(Sc) selective antibodies. We report a method to purify infectious PrP(Sc) from biological tissues for use as an immunogen and sample enrichment for increased immunoassay sensitivity. Significant prion enrichment is accomplished by sucrose gradient centrifugation of infected tissue and isolation with detergent resistant membranes from lipid rafts (DRMs). At equivalent protein concentration a 50-fold increase in detectable PrP(Sc) was observed in DRM fractions relative to crude brain by direct ELISA. Sequential purification steps result in increased specific infectivity (DRM <20-fold and purified DRM immunogen <40-fold) relative to 1% crude brain homogenate. Purification of PrP(Sc) from DRM was accomplished using phosphotungstic acid protein precipitation after proteinase-K (PK) digestion followed by size exclusion chromatography to separate PK and residual protein fragments from larger prion aggregates. Immunization with purified PrP(Sc) antigen was performed using wild-type (wt) and Prnp(0/0) mice, both on Balb/cJ background. A robust immune response against PrP(Sc) was observed in all inoculated Prnp(0/0) mice resulting in antisera containing high-titer antibodies against prion protein. Antisera from these mice recognized both PrP(C) and PrP(Sc), while binding to other brain-derived protein was not observed. In contrast, the PrP(Sc) inoculum was non-immunogenic in wt mice and antisera showed no reactivity with PrP or any other protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647769      PMCID: PMC2933057          DOI: 10.4161/pri.4.2.12622

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  38 in total

Review 1.  Prion protein and developments in its detection.

Authors:  I MacGregor
Journal:  Transfus Med       Date:  2001-02       Impact factor: 2.019

Review 2.  Molecular diagnostic tools in Creutzfeldt-Jakob disease and other prion disorders.

Authors:  Bart Van Everbroeck; Jef Boons; Evelyn De Leenheir; Ursula Lübke; Patrick Cras
Journal:  Expert Rev Mol Diagn       Date:  2004-05       Impact factor: 5.225

3.  Identification of two immunogenic domains of the prion protein--PrP--which activate class II-restricted T cells and elicit antibody responses against the native molecule.

Authors:  Sylvie Gregoire; Caroline Logre; Pat Metharom; Estelle Loing; Jacques Chomilier; Martine Bruley Rosset; Pierre Aucouturier; Claude Carnaud
Journal:  J Leukoc Biol       Date:  2004-04-01       Impact factor: 4.962

4.  Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.

Authors:  J D Wadsworth; S Joiner; A F Hill; T A Campbell; M Desbruslais; P J Luthert; J Collinge
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

5.  Attempts to demonstrate neutralising antibodies in the sera of scrapie-affected animals.

Authors:  M C Clarke; D A Haig
Journal:  Vet Rec       Date:  1966-05-07       Impact factor: 2.695

6.  Kinetics of prion protein accumulation in the CNS of mice with experimental scrapie.

Authors:  J Tatzelt; D F Groth; M Torchia; S B Prusiner; S J DeArmond
Journal:  J Neuropathol Exp Neurol       Date:  1999-12       Impact factor: 3.685

Review 7.  Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment.

Authors:  Stephen J DeArmond; Stanley B Prusiner
Journal:  Clin Lab Med       Date:  2003-03       Impact factor: 1.935

8.  Progress and problems in the biology, diagnostics, and therapeutics of prion diseases.

Authors:  Adriano Aguzzi; Mathias Heikenwalder; Gino Miele
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 9.  Subclinical prion infection.

Authors:  Andrew F Hill; John Collinge
Journal:  Trends Microbiol       Date:  2003-12       Impact factor: 17.079

Review 10.  Diagnosis of prion diseases.

Authors:  Eric Kübler; Bruno Oesch; Alex J Raeber
Journal:  Br Med Bull       Date:  2003       Impact factor: 4.291

View more
  4 in total

1.  Direct evidence of generation and accumulation of β-sheet-rich prion protein in scrapie-infected neuroblastoma cells with human IgG1 antibody specific for β-form prion protein.

Authors:  Toshiya Kubota; Yuta Hamazoe; Shuhei Hashiguchi; Daisuke Ishibashi; Kazuyuki Akasaka; Noriyuki Nishida; Shigeru Katamine; Suehiro Sakaguchi; Ryota Kuroki; Toshihiro Nakashima; Kazuhisa Sugimura
Journal:  J Biol Chem       Date:  2012-02-22       Impact factor: 5.157

2.  Effect of glycans and the glycophosphatidylinositol anchor on strain dependent conformations of scrapie prion protein: improved purifications and infrared spectra.

Authors:  Gerald S Baron; Andrew G Hughson; Gregory J Raymond; Danielle K Offerdahl; Kelly A Barton; Lynne D Raymond; David W Dorward; Byron Caughey
Journal:  Biochemistry       Date:  2011-05-03       Impact factor: 3.162

3.  Novel epitopes identified by anti-PrP monoclonal antibodies produced following immunization of Prnp0/0 Balb/cJ mice with purified scrapie prions.

Authors:  Larry H Stanker; Miles C Scotcher; Alice Lin; Jeffery McGarvey; Stanley B Prusiner; Robert Hnasko
Journal:  Hybridoma (Larchmt)       Date:  2012-10

4.  Na+/K+-ATPase is present in scrapie-associated fibrils, modulates PrP misfolding in vitro and links PrP function and dysfunction.

Authors:  James F Graham; Dominic Kurian; Sonya Agarwal; Lorna Toovey; Lawrence Hunt; Louise Kirby; Teresa J T Pinheiro; Steven J Banner; Andrew C Gill
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.